Integrative analysis of ATAC-seq and RNA-seq for cells infected by human T-cell leukemia virus type 1

PLoS Comput Biol. 2025 Jan 2;21(1):e1012690. doi: 10.1371/journal.pcbi.1012690. eCollection 2025 Jan.

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy (HAM) after a long latent period in a fraction of infected individuals. These HTLV-1-infected cells typically have phenotypes similar to that of CD4+T cells, but the cell status is not well understood. To extract the inherent information of HTLV-1-infected CD4+ cells, we integratively analyzed the ATAC-seq and RNA-seq data of the infected cells. Compared to CD4+T cells from healthy donors, we found anomalous chromatin accessibility in HTLV-1infected CD4+ cells derived from ATL cases in terms of location and sample-to-sample fluctuations in open chromatin regions. Further, by focusing on systematically selected genes near the open chromatin regions, we quantified the difference between the infected CD4+ cells in ATL cases and healthy CD4+T cells in terms of the correlation between the chromatin structures and the gene expressions. Based on a further analysis of chromatin accessibility, we detected TLL1 (Tolloid Like 1) as one of the key genes that exhibit unique gene expressions in ATL cases. A luciferase assay indicated that TLL1 has an isoform-dependent regulatory effect on TGF-β. Overall, this study provides results about the status of HTLV-1-infected cells, which are qualitatively consistent across the different scales of chromatin accessibility, transcription, and immunophenotype.

MeSH terms

  • CD4-Positive T-Lymphocytes* / virology
  • Chromatin / genetics
  • Chromatin / metabolism
  • Chromatin Immunoprecipitation Sequencing / methods
  • Computational Biology / methods
  • HTLV-I Infections / genetics
  • HTLV-I Infections / virology
  • Human T-lymphotropic virus 1* / genetics
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell* / genetics
  • Leukemia-Lymphoma, Adult T-Cell* / virology
  • RNA-Seq* / methods

Substances

  • Chromatin

Grants and funding

This work was supported by the Research Program on Emerging and Re-emerging Infectious Diseases (21fk0108088h0003 to J.Y. and M.M.) from the Japan Agency for Medical Research and Development (AMED), grant from the Naito Foundation (to A.T.), and KAKENHI (23H02936 to J.Y.; 19H03689 to M.M.; 21K06393 to H.T.; JP19K16740 and JP18J40119 to A.T.) from the JSPS. This study was also supported in part by the JSPS Core-to-Core Program A, Advanced Research Networks (to J.Y. and M.M). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.